Mike Hotra joins the organization as VP of its public affairs team, and Ken McKay is the advocacy organization’s new VP state government affairs.
Rachel Sher was most recently a senior policy analyst in the Food and Drug Administration’s Office of Policy.
The approval adds to the 5-, 10-, 15-, 20- and 30-mg capsules the company has previously launched of the generic.
Vigamox ophthalmic solution had U.S. sales of approximately $267.9 million, according to Quintiles IMS data for the 12 months ended March 2017.
Advent International is buying the Mexican private generics leader from Endo for roughly $124 million.
The drug had annual market sales of $248 million for the 12 months ended April 2017.
Under the agreement, Sandoz will develop and commercialize a generic of a major inhaled combination therapy delivered using a pressurized metered dose inhaler that Vectura Group is developing.
The drug had combined sales of $188 million for the 12 months ended April 2017, the company said.
The company said that the creams had combined U.S. sales of $38 million for the 12 months ended Aril 2017, according to QuintilesIMS data.